EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #17861_C
免疫磁珠正选细胞分选试剂盒
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
使用 EasySep™ 人 Pan-CD25 正选与去除试剂盒，可通过免疫磁性正选法轻松从新鲜人外周血单个核细胞（PBMCs）或裂解的白细胞单采样本中分选或去除 CD25⁺ 细胞。EasySep™ 技术在发表研究中已广泛使用超过 20 年，结合了单克隆抗体的特异性与无柱式分选的简便性。
在此 EasySep™ 正选步骤中，目标细胞经识别 CD25 的抗体复合物与磁珠标记。通过 EasySep™ 磁体分离后，未标记的细胞被去除，CD25⁺ 细胞保留在管中。完成磁性细胞分离后，任一组分中的目标细胞均可直接用于下游应用，如流式细胞术、体外实验或细胞培养。CD25 抗原表达于调节性 T 细胞以及活化的 T 和 B 细胞上。
了解更多有关 EasySep™ 免疫磁性技术的工作原理，或了解如何使用 RoboSep™ 实现免疫磁性细胞分离的全自动化，以节省时间并提高实验室通量。探索更多优化您实验流程的相关产品，包括培养基、补充物、抗体等。
磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
分类
细胞分选试剂盒
细胞类型
T 细胞，CD4+，T 细胞，调节性细胞
种属
人
样本来源
PBMC
分选方法
去除
应用
细胞分选
品牌
EasySep
研究领域
免疫
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (9)
文献 (2)
CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 N141I neurons. Acta neuropathologica communications 2017 dec
Abstract
Basal forebrain cholinergic neurons (BFCNs) are believed to be one of the first cell types to be affected in all forms of AD, and their dysfunction is clinically correlated with impaired short-term memory formation and retrieval. We present an optimized in vitro protocol to generate human BFCNs from iPSCs, using cell lines from presenilin 2 (PSEN2) mutation carriers and controls. As expected, cell lines harboring the PSEN2 N141I mutation displayed an increase in the A$\beta$42/40 in iPSC-derived BFCNs. Neurons derived from PSEN2 N141I lines generated fewer maximum number of spikes in response to a square depolarizing current injection. The height of the first action potential at rheobase current injection was also significantly decreased in PSEN2 N141I BFCNs. CRISPR/Cas9 correction of the PSEN2 point mutation abolished the electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in controls. Increased A$\beta$42/40 was also normalized following CRISPR/Cas-mediated correction of the PSEN2 N141I mutation. The genome editing data confirms the robust consistency of mutation-related changes in A$\beta$42/40 ratio while also showing a PSEN2-mutation-related alteration in electrophysiology.
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Scientific reports 2017 AUG
Abstract
Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus. Elimination of these reservoirs through the administration of synergistic combinations of latency reversing agents (LRAs), such as histone deacetylase (HDAC) inhibitors and protein kinase C (PKC) modulators, provides a promising strategy to reduce if not eradicate the viral reservoir. Here, we demonstrate that largazole and its analogues are isoform-targeted histone deacetylase inhibitors and potent LRAs. Significantly, these isoform-targeted HDAC inhibitors synergize with PKC modulators, namely bryostatin-1 analogues (bryologs). Implementation of this unprecedented LRA combination induces HIV-1 reactivation to unparalleled levels and avoids global T-cell activation within resting CD4+ T-cells.
更多信息
| 物种 | 人类 |
|---|---|
| Magnet Compatibility | • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) |
| 样本来源 | PBMC |
| Selection Method | Depletion |
相关产品
-
冻存的人外周血单个核细胞冻存的人原代细胞
沪公网安备31010102008431号
在线联系